We are a pharmatech company, leveraging a systems-modelling approach to develop the next generation of immuno-oncology biologics, enabled by our technical innovation in physics-first biophysical modelling + AI.
The 85% attrition rate at clinical trial for immuno-oncology therapies, which costs pharma $50billion+ year in failed trials, has been attributed to the lack of quality predictive pre-clinical models. We believe that a systems-based approach to in-silico modelling is the clear-cut solution to this problem. Organising our existing understanding in a highly interpretable platform to design, develop and re-engineer biologics therapies.
Our technology combines physics, biology and AI to enable a ground-breaking shift in our ability to model and simulate complex disease systems, generating living data.
Our patent-pending technology reduces parameter uncertainty by up to 100x compared with existing biophysical or AI approaches, reducing data requirements by 10-20x. This is an order of magnitude shift, unlocking new possibilities for in-silico modelling of large-scale complex disease systems. This patent-pending innovation is at the core of Bioleap's mission.
Enabled by interdisciplinary technical innovation, our mindset is one of open-ness: to challenge, to innovation and to research. Collaboration, breaking barriers, removing silos - with rigorous scientific intention and creative endeavour.
We're taking on the greatest challenges facing biology. For that we're going to need the brightest minds - creating an ecosystem that proves an environment to solve problems that have never been solved before.
Mekka
Runne
Lumos
Quali
